ERVW-1 and neoplasm: Manipulating envelope glycoproteins of HSVs for oncolytic virotherapy would achieve strict targeting of tumor cells as well as complete de-targeting from healthy tissues to allow maximum oncolytic efficacy and minimum adverse effects.